Market revenue in 2023 | USD 26.5 million |
Market revenue in 2030 | USD 32.4 million |
Growth rate | 2.9% (CAGR from 2023 to 2030) |
Largest segment | Fecal occult blood tests |
Fastest growing segment | Biomarker tests |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Fecal Occult Blood Tests, Biomarker tests, CRC DNA Screening Tests |
Key market players worldwide | Abbott Laboratories, Epigenomics AG, Beckman Coulter, Eiken Chemical Co Ltd, Sysmex Corp, Siemens Healthineers AG ADR, Quest Diagnostics Inc, OncoCyte Corp, Merck KGaA, Kyowa Kirin Co Ltd, R-Biopharm, Immunostics, Randox |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to in-vitro colorectal cancer screening tests market will help companies and investors design strategic landscapes.
Fecal occult blood tests was the largest segment with a revenue share of 81.89% in 2023. Horizon Databook has segmented the Brazil in-vitro colorectal cancer screening tests market based on fecal occult blood tests, biomarker tests, crc dna screening tests covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil in-vitro colorectal cancer screening tests market , including forecasts for subscribers. This country databook contains high-level insights into Brazil in-vitro colorectal cancer screening tests market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account